Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study
Frontiers in Oncology · 11.05.2026 · 16
DOI: 10.3389/fonc.2026.1751879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 11.05.2026. Verfasst von Tomonori Kawasaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Saitama Medical University.
Abstract (Originalsprache)
Introduction
Bone and soft tissue sarcomas are rare, heterogeneous malignancies with limited treatment options for advanced stages. Pembrolizumab, an anti-PD-1 immune checkpoint inhibitor (ICI), is approved for tumors exhibiting high microsatellite instability (MSI-high) or high tumor mutation burden (TMB-high); however, its efficacy remains unclear.
Methods
We reviewed records of 40 patients with advanced/recurrent sarcoma who underwent genomic profiling. MSI status and TMB were assessed using the NCC Oncopanel ® or FoundationOne ® . Patients identified as MSI-high and/or TMB-high received pembrolizumab (200 mg/body weight every 3 weeks). Clinical outcomes were evaluated using RECIST v1.1 and adverse events graded per CTCAE v5.0.
Results
Three patients (7.5%) were MSI-high and/or TMB-high: one each with undifferentiated pleomorphic bone sarcoma, leiomyosarcoma, and dedifferentiated chondrosarcoma. All had metastatic disease and received chemotherapy. Pembrolizumab was administered for 5–25 cycles for 5–18 months. Two patients achieved a partial response, and one had stable disease, yielding an objective response rate of 67% and a mean response duration of 12.7 months. No complete response or disease progression occurred. The adverse events were limited to grade 2 thyroid dysfunction and skin toxicity. No grade ≥3 events or treatment discontinuations occurred.
Conclusion
Pembrolizumab demonstrated promising efficacy and tolerability in MSI-high/TMB-high sarcomas. These findings support biomarker-driven immunotherapy in patients with sarcomas. Comprehensive genomic profiling should be considered in refractory cases. Further studies are warranted to validate these results and explore additional biomarkers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
- Department of Orthopedic Oncology and Surgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
- Department of Orthopedic Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
- Department of Clinical Cancer Genomics, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
- Department of Orthopedic Surgery, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Förderung
- Saitama Medical University
Zitieren
APA
Kawasaki, T., Torigoe, T., Tsujimoto, D., Watanabe, T., Hirasaki, M., Kamakura, Y., Wako, M., Mitsui, K., & Ichikawa, J. (2026). Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1751879
Vancouver
Kawasaki T, Torigoe T, Tsujimoto D, Watanabe T, Hirasaki M, Kamakura Y, et al. Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1751879
BibTeX
@article{Kawasaki2026,
author = {Kawasaki, Tomonori and Torigoe, Tomoaki and Tsujimoto, Daisuke and Watanabe, Takuya and Hirasaki, Masataka and Kamakura, Yasuo and Wako, Masanori and Mitsui, Kouhei and Ichikawa, Jiro},
title = {Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1751879}
}
EUVIMED